Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

Recent Analyst Ratings for
$ELEV

Recent Analyst Ratings for
$ELEV

$ELEV
Analyst Ratings

$ELEV
Press Releases

$ELEV
Insider Trading

$ELEV
SEC Filings

$ELEV
Leadership Updates

$ELEV
Large Ownership Changes

Crush Q1 2026 with the Best AI Superconnector

Crush Q1 2026 with the Best AI Superconnector

Elevation Oncology downgraded by Stephens with a new price target

Elevation Oncology downgraded by Leerink Partners with a new price target

Elevation Oncology downgraded by Citizens JMP

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

SEC Form 4 filed by Director Sandler Alan B.

SEC Form 4 filed by Director Mootz Darcy

SEC Form 4 filed by Director Elms Steve

SEC Form 15-12G filed by Elevation Oncology Inc.

SEC Form EFFECT filed by Elevation Oncology Inc.

SEC Form EFFECT filed by Elevation Oncology Inc.

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

7/15/24 1:17:58 PM ET

$ELEV

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ELEV alert in real time by email

SC 13G/A 1 d854392dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Elevation Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

28623U101

(CUSIP Number)

July 11, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 28623U101

(1)

Consists of 3,457,926 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

Consists of 1,246,488 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

Consists of 424,206 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

Consists of 864,959 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

Consists of (i) 3,457,926 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 1,246,488 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 424,206 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 864,959 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

Consists of (i) 3,457,926 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 1,246,488 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.


Item 1(a).		Name of Issuer: Elevation Oncology, Inc.

Item 1(b).		Address of Issuer’s Principal Executive Offices: 101 Federal Street, Suite 1900, Boston, MA 02110

Item 2(a).		Name of Person Filing:

		The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

		Frazier Life Sciences Public Fund, L.P. (“FLSPF”)
		FHMLSP, L.P.
		FHMLSP, L.L.C.
		Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”)
		FHMLSP Overage, L.P.
		FHMLSP Overage, L.L.C.
		Frazier Life Sciences XI, L.P. (“FLS XI”)
		FHMLS XI, L.P.
		FHMLS XI, L.L.C.
		Frazier Life Sciences X, L.P. (“FLS X”)
		FHMLS X, L.P.
		FHMLS X, L.L.C.
		James N. Topper (“Topper”)
		Patrick J. Heron (“Heron”)
		Albert Cha (“Cha”)
		James Brush (“Brush”)
		Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).		Address of Principal Business Office or, if none, Residence:

		The address and principal business office of the Reporting Persons is:

		c/o Frazier Life Sciences Management, L.P.
		1001 Page Mill Rd, Building 4, Suite B
		Palo Alto, CA 94304



Item 2(c).	Citizenship:

	Entities:	FLSPF	-	Delaware, U.S.A.
		FHMLSP, L.P.	-	Delaware, U.S.A.
		FHMLSP, L.L.C.	-	Delaware, U.S.A.
		FLSPOF	-	Delaware, U.S.A.
		FHMLSP Overage, L.P.	-	Delaware, U.S.A.
		FHMLSP, L.L.C.	-	Delaware, U.S.A.
		FLS XI	-	Delaware, U.S.A.
		FHMLS XI, L.P.	-	Delaware, U.S.A.
		FHMLS XI, L.L.C.	-	Delaware, U.S.A.
		FLS X	-	Delaware, U.S.A.
		FHMLS X, L.P.	-	Delaware, U.S.A.
		FHMLS X, L.L.C.	-	Delaware, U.S.A.

	Individuals:	Topper	-	United States Citizen
		Heron	-	United States Citizen
		Cha	-	United States Citizen
		Brush	-	United States Citizen
		Estes	-	United States Citizen



Item 2(d).		Title of Class of Securities: Common Stock

Item 2(e).		CUSIP Number: 28623U101



Item 3.	If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);


(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: July 15, 2024	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
	By: FHMLSP Overage, L.P., its General Partner
	By: FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP OVERAGE, L.P.
	By FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP OVERAGE, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FRAZIER LIFE SCIENCES XI, L.P.
	By: FHMLS XI, L.P., its General Partner
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLS XI, L.P.

	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: July 15, 2024	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FRAZIER LIFE SCIENCES X, L.P.
	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	By:	*
		James N. Topper

Date: July 15, 2024	By:	*
		Patrick J. Heron

Date: July 15, 2024	By:	**
		Albert Cha

Date: July 15, 2024	By:	**
		James Brush

Date: July 15, 2024	By:	***
		Daniel Estes

Date: July 15, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index


Exhibit A -		Agreement regarding filing of joint Schedule 13G.

Get the next $ELEV alert in real time by email

Recent Analyst Ratings for

$ELEV

Date	Price Target	Rating	Analyst
3/24/2025	$5.00 → $1.00	Overweight → Equal-Weight	Stephens
3/21/2025	$1.00	Outperform → Market Perform	Leerink Partners
3/21/2025		Mkt Outperform → Mkt Perform	Citizens JMP
3/21/2025	$0.70	Overweight → Neutral	Piper Sandler
1/3/2025		Outperform	William Blair
5/31/2024	$10.00	Overweight	Piper Sandler
5/14/2024	$8.00	Overweight	Stephens
3/1/2024	$7.00	Mkt Outperform	JMP Securities

More analyst ratings

7/15/24 1:17:58 PM ET

$ELEV

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ELEV alert in real time by email

SC 13G/A 1 d854392dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Elevation Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

28623U101

(CUSIP Number)

July 11, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.

CUSIP No. 28623U101

(1)

(2)	Based on 54,638,262 shares of Common Stock outstanding on April 26, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 2, 2024.


Item 1(a).		Name of Issuer: Elevation Oncology, Inc.

Item 1(b).		Address of Issuer’s Principal Executive Offices: 101 Federal Street, Suite 1900, Boston, MA 02110

Item 2(a).		Name of Person Filing:

		The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

		Frazier Life Sciences Public Fund, L.P. (“FLSPF”)
		FHMLSP, L.P.
		FHMLSP, L.L.C.
		Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”)
		FHMLSP Overage, L.P.
		FHMLSP Overage, L.L.C.
		Frazier Life Sciences XI, L.P. (“FLS XI”)
		FHMLS XI, L.P.
		FHMLS XI, L.L.C.
		Frazier Life Sciences X, L.P. (“FLS X”)
		FHMLS X, L.P.
		FHMLS X, L.L.C.
		James N. Topper (“Topper”)
		Patrick J. Heron (“Heron”)
		Albert Cha (“Cha”)
		James Brush (“Brush”)
		Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).		Address of Principal Business Office or, if none, Residence:

		The address and principal business office of the Reporting Persons is:

		c/o Frazier Life Sciences Management, L.P.
		1001 Page Mill Rd, Building 4, Suite B
		Palo Alto, CA 94304



Item 2(c).	Citizenship:

	Entities:	FLSPF	-	Delaware, U.S.A.
		FHMLSP, L.P.	-	Delaware, U.S.A.
		FHMLSP, L.L.C.	-	Delaware, U.S.A.
		FLSPOF	-	Delaware, U.S.A.
		FHMLSP Overage, L.P.	-	Delaware, U.S.A.
		FHMLSP, L.L.C.	-	Delaware, U.S.A.
		FLS XI	-	Delaware, U.S.A.
		FHMLS XI, L.P.	-	Delaware, U.S.A.
		FHMLS XI, L.L.C.	-	Delaware, U.S.A.
		FLS X	-	Delaware, U.S.A.
		FHMLS X, L.P.	-	Delaware, U.S.A.
		FHMLS X, L.L.C.	-	Delaware, U.S.A.

	Individuals:	Topper	-	United States Citizen
		Heron	-	United States Citizen
		Cha	-	United States Citizen
		Brush	-	United States Citizen
		Estes	-	United States Citizen



Item 2(d).		Title of Class of Securities: Common Stock

Item 2(e).		CUSIP Number: 28623U101



Item 3.	If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);


(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: July 15, 2024	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
	By: FHMLSP Overage, L.P., its General Partner
	By: FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP OVERAGE, L.P.
	By FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLSP OVERAGE, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FRAZIER LIFE SCIENCES XI, L.P.
	By: FHMLS XI, L.P., its General Partner
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLS XI, L.P.

	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: July 15, 2024	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FRAZIER LIFE SCIENCES X, L.P.
	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: July 15, 2024	By:	*
		James N. Topper

Date: July 15, 2024	By:	*
		Patrick J. Heron

Date: July 15, 2024	By:	**
		Albert Cha

Date: July 15, 2024	By:	**
		James Brush

Date: July 15, 2024	By:	***
		Daniel Estes

Date: July 15, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index


Exhibit A -		Agreement regarding filing of joint Schedule 13G.

Get the next $ELEV alert in real time by email

Recent Analyst Ratings for

$ELEV

Date	Price Target	Rating	Analyst
3/24/2025	$5.00 → $1.00	Overweight → Equal-Weight	Stephens
3/21/2025	$1.00	Outperform → Market Perform	Leerink Partners
3/21/2025		Mkt Outperform → Mkt Perform	Citizens JMP
3/21/2025	$0.70	Overweight → Neutral	Piper Sandler
1/3/2025		Outperform	William Blair
5/31/2024	$10.00	Overweight	Piper Sandler
5/14/2024	$8.00	Overweight	Stephens
3/1/2024	$7.00	Mkt Outperform	JMP Securities

More analyst ratings

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware